Found: 28
Select item for more details and to access through your institution.
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER.
- Published in:
- Depression & Anxiety (1091-4269), 2015, v. 32, n. 6, p. 451, doi. 10.1002/da.22365
- By:
- Publication type:
- Article
Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder.
- Published in:
- JAMA: Journal of the American Medical Association, 2004, v. 291, n. 1, p. 40, doi. 10.1001/jama.291.1.40-a
- By:
- Publication type:
- Article
COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF AÂ PATIENT-REPORTED QUESTIONNAIRE FROM AÂ DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY.
- Published in:
- Schizophrenia Bulletin, 2020, v. 46, p. S117, doi. 10.1093/schbul/sbaa031.274
- By:
- Publication type:
- Article
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality.
- Published in:
- BMC Psychiatry, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12888-023-05017-y
- By:
- Publication type:
- Article
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis.
- Published in:
- Patient Preference & Adherence, 2021, v. 15, p. 2239, doi. 10.2147/PPA.S322880
- By:
- Publication type:
- Article
Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.
- Published in:
- Patient Preference & Adherence, 2020, v. 14, p. 1093, doi. 10.2147/PPA.S251812
- By:
- Publication type:
- Article
Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression.
- Published in:
- Neuropsychiatric Disease & Treatment, 2022, v. 18, p. 1127, doi. 10.2147/NDT.S358367
- By:
- Publication type:
- Article
Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials.
- Published in:
- Neuropsychiatric Disease & Treatment, 2021, v. 17, p. 3459, doi. 10.2147/NDT.S339090
- By:
- Publication type:
- Article
Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials.
- Published in:
- Neuropsychiatric Disease & Treatment, 2021, v. 17, p. 2347, doi. 10.2147/NDT.S314874
- By:
- Publication type:
- Article
Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia.
- Published in:
- Neuropsychiatric Disease & Treatment, 2020, v. 16, p. 3197, doi. 10.2147/NDT.S286654
- By:
- Publication type:
- Article
Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
- Published in:
- Journal of Psychopharmacology, 2023, v. 37, n. 8, p. 836, doi. 10.1177/02698811221123046
- By:
- Publication type:
- Article
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
- Published in:
- CNS Drugs, 2021, v. 35, n. 1, p. 39, doi. 10.1007/s40263-020-00779-5
- By:
- Publication type:
- Article
Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
- Published in:
- Clinical Drug Investigation, 2018, v. 38, n. 8, p. 695, doi. 10.1007/s40261-018-0647-z
- By:
- Publication type:
- Article
Male Sexual Disorder.
- Published in:
- 2005
- By:
- Publication type:
- Letter
Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies.
- Published in:
- Brazilian Journal of Psychiatry / Revista Brasileira de Psiquiatria, 2019, v. 41, n. 6, p. 499, doi. 10.1590/1516-4446-2018-0153
- By:
- Publication type:
- Article
Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia.
- Published in:
- Early Intervention in Psychiatry, 2020, v. 14, n. 4, p. 428, doi. 10.1111/eip.12868
- By:
- Publication type:
- Article
An assessment of injection site reaction and injection site pain of 1‐month and 3‐month long‐acting injectable formulations of paliperidone palmitate.
- Published in:
- Perspectives in Psychiatric Care, 2018, v. 54, n. 4, p. 530, doi. 10.1111/ppc.12267
- By:
- Publication type:
- Article
Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with Schizophrenia.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies.
- Published in:
- Neuropsychiatric Disease & Treatment, 2020, v. 16, p. 1533, doi. 10.2147/NDT.S221242
- By:
- Publication type:
- Article
Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study.
- Published in:
- Neuropsychiatric Disease & Treatment, 2020, v. 16, p. 681, doi. 10.2147/NDT.S226296
- By:
- Publication type:
- Article
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia.
- Published in:
- Neuropsychiatric Disease & Treatment, 2019, v. 15, p. 1365, doi. 10.2147/NDT.S197225
- By:
- Publication type:
- Article
Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation.
- Published in:
- Neuropsychiatric Disease & Treatment, 2019, v. 15, p. 731, doi. 10.2147/NDT.S194264
- By:
- Publication type:
- Article
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate.
- Published in:
- Neuropsychiatric Disease & Treatment, 2018, v. 14, p. 2807, doi. 10.2147/NDT.S175364
- By:
- Publication type:
- Article
Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study.
- Published in:
- Neuropsychiatric Disease & Treatment, 2018, v. 14, p. 1107, doi. 10.2147/NDT.S157399
- By:
- Publication type:
- Article
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
- Published in:
- Neuropsychiatric Disease & Treatment, 2017, v. 13, p. 2193, doi. 10.2147/NDT.S134287
- By:
- Publication type:
- Article
Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study.
- Published in:
- Neuropsychiatric Disease & Treatment, 2017, v. 13, p. 2021, doi. 10.2147/NDT.S130211
- By:
- Publication type:
- Article